In February 2026, Cannabis Bioscience International Holdings, Inc. expanded its board by adding a key mergers and acquisitions expert, signaling a strategic focus on growth and corporate development.

• Cannabis Bioscience expanded its board by adding a key M&A expert in February 2026 [N1].

The company’s diversified business model spanning education, clinical trials, and CBD product development positions it to capitalize on the expanding legal cannabis and hemp markets. Its intellectual property portfolio and ongoing patent filings could provide proprietary advantages in cannabinoid therapeutics. Active participation in regulatory discourse and DEA hearings may enhance its influence and access to federally sanctioned research opportunities. The recent addition of a key M&A expert to the board may facilitate strategic partnerships or acquisitions to accelerate growth.

Cannabis Bioscience faces significant challenges including limited financial resources, liquidity constraints, and reliance on a small number of customers for clinical trial revenues. The regulatory environment for cannabis and CBD products remains complex and uncertain, with federal illegality persisting despite state-level legalization. The company’s modest revenue and net losses highlight operational risks. Competition from larger, better-funded companies with more extensive resources and capabilities may limit Cannabis Bioscience’s ability to scale and compete effectively.

Cannabis Bioscience’s moat is based on its specialized intellectual property portfolio comprising multiple patent applications and trademarks related to cannabinoid formulations and medical treatments. Its integrated approach combining education, clinical research, and product development in the medicinal cannabis space provides a differentiated platform. The company’s active engagement in regulatory processes and its established relationships with law enforcement and research institutions further support its competitive positioning. However, the company operates with substantially lower capital and manpower compared to larger industry players, which may limit scale and market reach.

• Regulatory and Legal Risks: The company operates in a highly regulated industry with ongoing federal illegality of cannabis. Changes in enforcement policies or regulatory frameworks could adversely affect operations.
• Financial and Liquidity Risks: The company shows liquidity constraints with current liabilities exceeding current assets and a low cash ratio, which may impact its ability to fund operations and growth.
• Customer Concentration Risk: A significant portion of clinical trial revenues is derived from a few customers, creating dependency and potential revenue volatility.
• Competitive Risk: The company competes with larger firms possessing greater financial resources, which may limit its market share and ability to attract contracts or partnerships.

• Cannabis Bioscience International Holdings, Inc. operates three main businesses: Pharmacology University (cannabis-related research and education), Alpha Research Institute (clinical trials including cannabis and CBD products as Sponsor and CRO), and a CBD product business under the name VitaCookies.
• The company was originally formed in 2003 and has undergone several name changes, adopting its current name in December 2022.
• Pharmacology University provides cannabis education and research but does not cultivate, sell, or distribute cannabis products.
• Alpha Research Institute conducts clinical trials across multiple therapeutic areas and plans to conduct cannabinoid clinical trials as a Sponsor.
• The company plans to manufacture, market, and sell CBD products (VitaCookies) initially within Texas, complying with state laws and monitoring legal developments in other states before expansion.
• Cannabis Bioscience holds an intellectual property portfolio including 10 utility patent applications filed with the USPTO, 12 U.S. trademarks, and over 100 medical formulations targeting various conditions such as menopause, PTSD, depression, and Alzheimer’s disease.
• The company actively participates in regulatory and public policy discourse, including testimony at the DEA’s 2024 hearing on marijuana rescheduling.
• The U.S. cannabis industry is rapidly growing with increasing legalization and research opportunities, which the company views as a significant market opportunity for its educational and research services.
• The company’s clinical trials business generated revenues of approximately $301,731 for the year ended May 31, 2025, with revenues concentrated among a few customers.
• Cannabis Bioscience leases office space in Houston, Texas, and employs two full-time executive officers plus approximately 14 independent contractors.
• The company’s financial snapshot as of February 28, 2026, shows cash and equivalents of $73,498, current assets of $1,544, current liabilities of $1,219,174, revenue of $11,205, and a net loss of $103,933 for the quarter.
• Liquidity ratios derived from SEC data indicate a cash ratio of 0.06 and a current ratio of 0 as of February 28, 2026, reflecting a liquidity constraint.
• The company expanded its board by adding a key M&A expert as reported in February 2026 [N1].
• The company complies with applicable cannabis and clinical trial regulations and monitors evolving legal frameworks, particularly in Texas where it operates its CBD business.
• The company’s educational content includes eBooks, audiobooks, and video courses published on multiple platforms and in multiple languages, with ongoing investment in digital products.
• The company is a smaller reporting company and is not required to provide extensive risk factor disclosures under SEC rules.